

This spreadsheet is updated monthly and enables self-audit of a medicines formulary for adherence to current NICE Technology Appraisals. All guidelines refer to adults unless indicated.

Technology appraisals 53
 ICB commissioned 13
 Non-ICB commissioned 28
 Not applicable 13
 ICB commissioned and approved 13 (100%)
 Average days to compliance 45

Title	Recommendation	Published	Type	Implement	Commissioner	ICB decision	Compliance	Notes	Local information
Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency [TA963]	Recommended	03/04/2024	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Cabozantinib with nivolumab for untreated advanced renal cell carcinoma [TA964]	Recommended	10/04/2024	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer (terminated appraisal) [TA966]	Terminated appraisal	24/04/2024	TA					N/A	Terminated appraisal
Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) [TA968]	Terminated appraisal	25/04/2024	TA					N/A	Terminated appraisal
Gefapixant for treating refractory or unexplained chronic cough (terminated appraisal) [TA969]	Terminated appraisal	30/04/2024	TA					N/A	Terminated appraisal
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over [TA967]	Recommended	01/05/2024	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 [TA971]	Recommended	08/05/2024	TA (EAMS)	07/06/2024	ICB	25/06/2024	48	These technologies are commissioned by integrated care boards. Providers are NHS hospital trusts	Red statement for remdesivir. Black RAG for tixagevimab plus cilgavimab
Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatments [TA970]	Recommended	08/05/2024	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under [TA975]	Recommended	15/05/2024	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma [TA972]	Recommended	15/05/2024	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Atogepant for preventing migraine [TA973]	Recommended	15/05/2024	TA	13/08/2024	ICB	18/07/2024	64	This technology is commissioned by ICBs. Providers are secondary care acute hospital trusts (headache clinic) or primary care GP.	Amber retained statement
Ranibizumab for treating choroidal neovascularisation associated with pathological myopia [TA298]	Recommended	20/05/2024	TA (Update)		ICB			TA update. The wording of the recommendation describing the patient access scheme has been updated to include procurement information about ranibizumab biosimilars.	Red RAG rating

Title	Recommendation	Published	Type	Implement	Commissioner	ICB decision	Compliance	Notes	Local information
Ranibizumab and pegaptanib for the treatment of age-related macular degeneration [TA155]	Recommended	20/05/2024	TA (Update)		ICB			TA update. The wording of the recommendation describing the patient access scheme has been updated to include procurement information about ranibizumab biosimilars.	Red RAG rating
Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion [TA283]	Recommended	20/05/2024	TA (Update)		ICB			TA update. The wording of the recommendation describing the patient access scheme has been updated to include procurement information about ranibizumab biosimilars.	Red RAG rating
Cladribine for treating relapsing–remitting multiple sclerosis [TA616]	Recommended	21/05/2024	TA		Non-ICB			TA update. The wording in has been updated to address concerns raised by the clinical community and company that the previously used definition of rapidly evolving severe multiple sclerosis (RES) was overly restrictive. This is because the requirement for 2 MRI scans places significant burden on a limited diagnostic and monitoring resource. The wording has now been changed to better reflect clinical practice.	NHS England
Alemtuzumab for treating highly active relapsing–remitting multiple sclerosis [TA312]	Recommended	21/05/2024	TA		Non-ICB			TA update. The wording in has been updated to address concerns raised by the clinical community and company that the previously used definition of rapidly evolving severe multiple sclerosis (RES) was overly restrictive. This is because the requirement for 2 MRI scans places significant burden on a limited diagnostic and monitoring resource. The wording has now been changed to better reflect clinical practice.	NHS England
Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis [TA127]	Recommended	21/05/2024	TA		Non-ICB			TA update. The wording in has been updated to address concerns raised by the clinical community and company that the previously used definition of rapidly evolving severe multiple sclerosis (RES) was overly restrictive. This is because the requirement for 2 MRI scans places significant burden on a limited diagnostic and monitoring resource. The wording has now been changed to better reflect clinical practice.	NHS England
Sirolimus for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over (terminated appraisal) [TA972]	Terminated appraisal	22/05/2024	TA					NICE is unable to make a recommendation because the company did not provide an evidence submission. NICE will review this decision if the company decides to make a submission.	Terminated appraisal
Zanubrutinib with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma after 2 or more treatments (terminated appraisal) [TA978]	Terminated appraisal	29/05/2024	TA					NICE is unable to make a recommendation because the company did not provide an evidence submission. NICE will review this decision if the company decides to make a submission.	Terminated appraisal
Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over [TA977]	Recommended	29/05/2024	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Trastuzumab deruxtecan for treating HER2-mutated advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) [TA976]	Terminated appraisal	29/05/2024	TA					NICE is unable to make a recommendation because the company did not provide an evidence submission. NICE will review this decision if the company decides to make a submission.	Terminated appraisal

Title	Recommendation	Published	Type	Implement	Commissioner	ICB decision	Compliance	Notes	Local information
Nivolumab for adjuvant treatment of completely resected melanoma at high risk of recurrence in people 12 years and over (terminated appraisal) [TA980]	Terminated appraisal	05/06/2024	TA					NICE is unable to make a recommendation because the company did not provide an evidence submission. NICE will review this decision if the company decides to make a submission.	Terminated appraisal
Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation [TA979]	Recommended	05/06/2024	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Pembrolizumab with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma [TA983]	Not recommended	12/06/2024	TA					N/A	Not recommended
Voxelotor for treating haemolytic anaemia caused by sickle cell disease [TA981]	Recommended	12/06/2024	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over (terminated appraisal) [TA982]	Terminated appraisal	13/06/2024	TA					N/A	Terminated appraisal
Tafamidis for treating transthyretin amyloidosis with cardiomyopathy [TA984]	Recommended	19/06/2024	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Selective internal radiation therapies for treating hepatocellular carcinoma [TA688]	Recommended	03/07/2024	TA		Non-ICB			The technologies are commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Selective internal radiation therapy with QuiremSpheres for treating unresectable advanced hepatocellular carcinoma [TA985]	Recommended	03/07/2024	TA		Non-ICB			The technologies are commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (terminated appraisal)	Terminated appraisal	10/07/2024	TA					N/A	Terminated appraisal
Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over [TA986]	Recommended	10/07/2024	TA	08/10/2024	ICB	15/08/2024	36	This technology is commissioned by NHS England for children and ICBs for adults. Providers are NHS hospital trusts.	Red RAG rating
Tenecteplase for treating acute ischaemic stroke [TA990]	Recommended	24/07/2024	TA (Cost comparison)	23/08/2024	ICB	15/08/2024	22	This technology is commissioned by integrated care boards. Providers are NHS hospital trusts.	Red RAG rating
Etranacogene dezaparovec for treating moderately severe or severe haemophilia B [TA989]	Recommended	24/07/2024	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis [TA988]	Recommended	24/07/2024	TA		Non-ICB			These technologies are commissioned by NHS England. Providers are NHS hospital trusts.	NHS England

Title	Recommendation	Published	Type	Implement	Commissioner	ICB decision	Compliance	Notes	Local information
Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy [TA992]	Not recommended	29/07/2024	TA					N/A	Not recommended
Abaloparatide for treating osteoporosis after menopause [TA991]	Recommended	07/08/2024	TA	05/11/2024	ICB	19/09/2024	43	This technology is commissioned by integrated care boards. Providers are NHS hospital trusts.	Red RAG rating
Burosumab for treating X-linked hypophosphataemia in adults [TA993]	Recommended	07/08/2024	TA		Non-ICB			These technologies are commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Enzalutamide for treating non-metastatic prostate cancer after radical prostatectomy or radiotherapy (terminated appraisal) [TA994]	Terminated appraisal	08/08/2024	TA					NICE is unable to make a recommendation because the company did not provide an evidence submission. NICE will review this decision if the company decides to make a submission.	N/A
Linzagolix for treating moderate to severe symptoms of uterine fibroids [TA996]	Recommended	14/08/2024	TA	12/11/2024	ICB	18/10/2024	65		Amber initiated statement
Reluqolix for treating hormone-sensitive prostate cancer [TA995]	Recommended	14/08/2024	TA	12/11/2024	ICB	17/10/2024	64	This technology is commissioned by integrated care boards. Providers are Primary care and NHS hospital trusts.	Amber retained statement
Risankizumab for treating moderately to severely active ulcerative colitis	Recommended	22/08/2024	TA (Cost comparison)	21/09/2024	ICB	19/09/2024	28	This technology is commissioned by integrated care boards. Providers are NHS hospital trusts.	Red RAG rating
Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer [TA737]	Recommended	29/08/2024	TA (Update)		Non-ICB			TA update. This guidance was partially updated by NICE technology appraisal guidance 997 on pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma.	NHS England
Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma [TA997]	Recommended	29/08/2024	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Vibegron for treating symptoms of overactive bladder syndrome [TA999]	Recommended	04/09/2024	TA	03/12/2024	ICB	17/10/2024	43	This technology is commissioned by integrated care boards. Providers are Primary care and NHS hospital trusts.	Green statement
Zanubrutinib for treating marginal zone lymphoma after anti-CD20-based treatment [TA1001]	Recommended	04/09/2024	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Iptacopan for treating paroxysmal nocturnal haemoglobinuria [TA1000]	Recommended	04/09/2024	TA		Non-ICB			This technology is commissioned by NHS England.	NHS England
Futibatinib for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement [TA1005]	Recommended	11/09/2024	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England

Title	Recommendation	Published	Type	Implement	Commissioner	ICB decision	Compliance	Notes	Local information
Faricimab for treating visual impairment caused by macular oedema after retinal vein occlusion [TA1004]	Recommended	11/09/2024	TA (Cost comparison)	11/10/2024	ICB	17/10/2024	36	This technology is commissioned by integrated care boards. Providers are NHS hospital trusts.	Red RAG rating
Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia in people 12 years and over [TA1003]	Recommended	11/09/2024	TA		Non-ICB			This technology is commissioned by NHS England.	NHS England
Evinacumab for treating homozygous familial hypercholesterolaemia in people 12 years and over [TA1002]	Recommended	11/09/2024	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS tertiary centres.	NHS England
Empagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal) [TA1006]	Terminated appraisal	12/09/2024	TA					N/A	Terminated appraisal
Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer [TA1007]	Recommended	17/09/2024	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments [TA1008]	Recommended	25/09/2024	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England